Evidence map›Paper›PMID 37063279›Full record

ArticleFrontiers in pharmacology2023

Microfluidic/HPLC combination to study carnosine protective activity on challenged human microglia: Focus on oxidative stress and energy metabolism.

Anna Privitera, Vincenzo Cardaci, Dhanushka Weerasekara, Miriam Wissam Saab, Lidia Diolosà, Annamaria Fidilio, Renaud Blaise Jolivet, Giuseppe Lazzarino, Angela Maria Amorini, Massimo Camarda and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Anna PriviteraDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.
Vincenzo CardaciVita-Salute San Raffaele University, Milano, Italy.
Dhanushka WeerasekaraRalph N. Adams Institute for Bioanalytical Chemistry, University of Kansas, Lawrence, KS, United States.
Miriam Wissam SaabDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Lidia DiolosàDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.
Annamaria FidilioUnit of Neuropharmacology and Translational Neurosciences, Oasi Research Institute-IRCCS, Troina, Italy.
Renaud Blaise JolivetMaastricht Centre for Systems Biology (MaCSBio), Maastricht University, Maastricht, Netherlands.
Giuseppe LazzarinoDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Angela Maria AmoriniDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Massimo CamardaSTLab Srl, Catania, Italy.
Susan Marie LunteRalph N. Adams Institute for Bioanalytical Chemistry, University of Kansas, Lawrence, KS, United States.
Filippo CaraciDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.
Giuseppe CarusoDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.
University of Catania · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Kansas · USMaastricht University · NLOasi Maria SS · IT

Funding

Synthetic Chemical Biology CoreP30GM145499 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Susan M Lunte · 2022 to 2026
$6.9M
NIGMS NIH HHS P30 GM145499
6 · The paper itself

Abstract

Carnosine (β-alanyl-L-histidine) is a naturally occurring endogenous peptide widely distributed in excitable tissues such as the brain. This dipeptide possesses well-demonstrated antioxidant, anti-inflammatory, and anti-aggregation properties, and it may be useful for treatment of pathologies characterized by oxidative stress and energy unbalance such as depression and Alzheimer's disease (AD). Microglia, the brain-resident macrophages, are involved in different physiological brain activities such synaptic plasticity and neurogenesis, but their dysregulation has been linked to the pathogenesis of numerous diseases. In AD brain, the activation of microglia towards a pro-oxidant and pro-inflammatory phenotype has found in an early phase of cognitive decline, reason why new pharmacological targets related to microglia activation are of great importance to develop innovative therapeutic strategies. In particular, microglia represent a common model of lipopolysaccharides (LPS)-induced activation to identify novel pharmacological targets for depression and AD and numerous studies have linked the impairment of energy metabolism, including ATP dyshomeostasis, to the onset of depressive episodes. In the present study, we first investigated the toxic potential of LPS + ATP in the absence or presence of carnosine. Our studies were carried out on human microglia (HMC3 cell line) in which LPS + ATP combination has shown the ability to promote cell death, oxidative stress, and inflammation. Additionally, to shed more light on the molecular mechanisms underlying the protective effect of carnosine, its ability to modulate reactive oxygen species production and the variation of parameters representative of cellular energy metabolism was evaluated by microchip electrophoresis coupled to laser-induced fluorescence and high performance liquid chromatography, respectively. In our experimental conditions, carnosine prevented LPS + ATP-induced cell death and oxidative stress, also completely restoring basal energy metabolism in human HMC3 microglia. Our results suggest a therapeutic potential of carnosine as a new pharmacological tool in the context of multifactorial disorders characterize by neuroinflammatory phenomena including depression and AD.

Indexed as

carnosinedepressionenergy metabolismHPLChuman microgliainflammationmicrofluidicsoxidative stress

Identifiers

PMID37063279
PMCPMC10095171
OpenAlexW4361301531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.